A SINGLE-CENTER REAL-LIFE EXPERIENCE WITH FIRST-LINE DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (DARA-VCD) IN AL AMYLOIDOSIS Metban Mastanzade, Meryem Merve Ören Çelik, Simge Erdem, Mustafa Murat Özbalak, İpek Yönal Hindilerden, Mustafa Nuri Yenerel, Sevgi Kalayoğlu Beşışık

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation Edvan De Queiroz Crusoe, Fabiana Higashi, Gracia Martinez, Rosane Bittencourt, Jorge Vaz Pinto Neto, Lais Sousa, Rodrigo Santucci, Roberto José Pessoa Magalhães, Gilberto Colli, Renata Ferreira Marques Nunes, Glaciano Ribeiro, Jandir Nicacio, Karla Richter Zanella, Jose Mauro Kutner, Andre Magalhaes, Danielle Leao, Abrahão Elias Hallack Neto, Walter Braga, Emanuella G Souza, Antonio Julio A.M. Guimaraes, Giovanna Steffenello Durigon, Dani Laks, Angelo Maiolino, Vania Tietsche de Moraes Hungria

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS E.Q. Crusoé, M.A. Salvino, H.H.M. Santos, A.S. Santos, A.M. Almeida, C.A. Fonseca, J.S. Leal, J.A. Santos, V.T.M. Hungria, M.G.B. Arruda